Twist Bioscience Corp

Twist Bioscience reported a 23.23% increase in third-quarter revenue to $118.4 million, but recorded a net loss of $35.1 million, a significant decline from a net income of $20.4 million in the prior year. For the nine months, net loss widened to $109.6 million. The company also announced an asset acquisition and equity investment in Invenra Inc. for its B-Body bispecific antibody discovery platform.

Twist Bioscience reported strong fiscal third quarter 2026 financial results, with revenue increasing 23% year-over-year to $118.4 million, marking its fourteenth consecutive quarter of sequential growth. The company raised its full fiscal year 2026 revenue guidance to $456-$457 million and reiterated its expectation to achieve adjusted EBITDA breakeven in Q4 FY26. Despite the revenue growth and improved gross margin, the company reported a net loss of $(35.1) million, compared to a net income in the prior year which included a significant gain from a business spin-out.

Twist Bioscience reported a 19.3% increase in Q1 2026 revenue to $110.7 million, alongside an increased net loss of $44.0 million. The company also announced a significant strategic move, acquiring a co-exclusive license to Invenra's B-Body bispecific antibody discovery platform for $20.0 million and making a $13.8 million equity investment in Invenra. Cash and cash equivalents saw a notable decrease during the period.

Twist Bioscience reported record fiscal second-quarter 2026 revenue of $110.7 million, a 19% increase year-over-year, marking its 13th consecutive quarter of growth. The company also improved its gross margin to 51.6% and raised its full fiscal year 2026 revenue guidance to $442-$447 million. Twist reiterated its expectation to achieve adjusted EBITDA breakeven in the fourth quarter of fiscal 2026, while also announcing new partnerships and product launches.